Clinical Trials in North Carolina

Showing 4761-4780 of 14,923 trials

A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility

NCT03065959

The purpose of this study is to investigate the effect of CK-2127107 versus placebo on skeletal muscle fatigue assessed as change from baseline versus 14 days of treatment in sum of peak torque during isokinetic knee extensions. This study will also assess the effects of CK-2127107 on physical performance via a short physical performance battery (SPPB), stair-climb test and 6 minute walk test.

Mobility Limitation

Astellas Pharma Global Development, Inc.42 participantsStarted Jun 2017

Gainesville, Florida, United States • Boston, Massachusetts, United States • St Louis, Missouri, United States +2 more locations

TERMINATEDPhase 241 miles

Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

NCT03973918

The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured by radiographic response in recurrent high-grade primary brain tumors.

High Grade GliomaBRAF V600EBRAF V600K+4 more

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins5 participantsStarted Jul 2019

Birmingham, Alabama, United States • Baltimore, Maryland, United States • Winston-Salem, North Carolina, United States

COMPLETED41 miles

Entyvio (Vedolizumab) Long Term Safety Study

NCT02674308

The purpose of this study is to assess the long-term safety of vedolizumab versus other biologic agents in participants with Ulcerative Colitis (UC) or Crohn's Disease (CD).

Ulcerative Colitis and Crohn's Disease

Takeda5,302 participantsStarted Mar 2015

Birmingham, Alabama, United States • Mobile, Alabama, United States • Tucson, Arizona, United States +284 more locations

A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility

Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

Entyvio (Vedolizumab) Long Term Safety Study

Find Trials by Condition in North Carolina

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

A Study of ASP1951 in Subjects With Advanced Solid Tumors

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers

Clareon Toric vs Eyhance Toric

A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD

A Multicenter Prospective Observational Study to Derive and Verify the Performance of a Host-response Based Diagnostic Tool for Early Detection of Severe Infections.

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome